GLP-1 Weight Loss Drugs: What They Cost and How to Pay

About 32 million American adults are now taking a GLP-1 medication, according to a June 2026 Gallup survey. That's roughly 12% of the adult population, more than double the share from early 2024. The U.S. obesity rate has actually dropped for the first time in modern tracking history, falling from 39.9% in 2022 to 36.8% so far this year.

These drugs work. The financial question is whether you can afford them.

The sticker price is brutal

Wegovy lists at roughly $1,350 to $1,640 per month without insurance. Zepbound runs around $1,060. Multiply either of those by twelve and you're looking at $12,000 to $19,000 a year, which is more than many people spend on their car.

If your employer plan covers it, your copay might land anywhere from $25 to several hundred dollars a month. But 27 million commercially insured Americans still have no coverage for Wegovy at all, according to GoodRx tracking data. Zepbound coverage varies just as widely. And even plans that technically cover GLP-1s often require prior authorization, step therapy (meaning you have to try and fail on cheaper treatments first), or both.

So the first step is calling your insurer and asking three specific questions: Is this drug on formulary? What tier? And what prior authorization hoops do I need to clear? Write down the answers, including the name of the representative you spoke with. You'll want that paper trail.

Medicare's new $50 bridge program

The biggest news of the summer for older adults: Medicare launched the GLP-1 Bridge Program on July 1, 2026. It covers Wegovy (injection and oral tablet), Zepbound (KwikPen), and Foundayo for a flat $50 copay per 30-day supply. The program runs through December 31, 2027.

To qualify, you need to be enrolled in a Medicare Part D plan (or a Medicare Advantage plan with drug coverage) and meet specific BMI criteria: a BMI of 35 or higher alone, or 27 or higher with related health conditions. The $50 copay does not count toward your Part D deductible or out-of-pocket maximum, which is worth knowing when you're budgeting.

The program is run centrally by CMS rather than through your individual Part D plan, so the approval process works differently than a typical prescription. Your doctor submits a request, and the bridge program handles the rest. If you're on Medicare and interested, bring this up at your next appointment. Many providers are still learning the process themselves.

Your HSA or FSA can help

Following IRS clarification in 2025, GLP-1 medications prescribed for obesity treatment qualify as medical expenses under HSA and FSA rules. That means you can use pre-tax dollars to pay for them, which effectively gives you a discount equal to your marginal tax rate.

For someone in the 22% federal bracket (plus state taxes), paying $200 a month out of an HSA saves roughly $50 to $60 a month compared to after-tax dollars. That adds up to $600 to $700 a year in tax savings alone.

The 2026 HSA contribution limit is $4,300 for individuals and $8,550 for families. The FSA limit is $3,300. If you're planning to use GLP-1s, max out your HSA contributions during open enrollment this fall. The triple tax advantage (tax-free contributions, growth, and withdrawals for medical expenses) makes HSAs one of the best deals in personal finance, and prescription drug costs are exactly what they're designed for.

One important note: your HSA eligibility depends on being enrolled in a high-deductible health plan. If you switch plans during open enrollment, double check that your new plan is HSA-compatible before you commit.

Manufacturer programs and self-pay options

Both Novo Nordisk and Eli Lilly offer savings programs, though the details matter.

The Wegovy savings card can reduce your copay to as low as $0, but it requires commercial insurance coverage. If your plan doesn't cover Wegovy at all, the card won't help. NovoCare, Novo Nordisk's patient assistance program, offers Wegovy to qualifying uninsured patients at reduced prices.

Eli Lilly takes a different approach with LillyDirect, selling Zepbound directly to self-pay patients for $399 to $549 per month. That's a steep discount from the $1,060 list price, and no insurance or coupon is required. They also offer a savings card for insured patients that can bring copays down to $25.

GoodRx coupons can shave some dollars off retail prices, but the savings on brand-name GLP-1s tend to be modest compared to manufacturer programs. Check both before filling a prescription.

Compounding pharmacies: cheaper, but read the fine print

Compounded semaglutide and tirzepatide became popular as a lower-cost alternative, typically running $200 to $400 per month through telehealth platforms. These are custom-mixed versions of the active ingredients, not the brand-name products.

There are legitimate compounding pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) or the National Association of Boards of Pharmacy (NABP). But the FDA has repeatedly warned about quality issues with some compounded GLP-1 products, including incorrect dosing and contamination.

If you go this route, ask for a Certificate of Analysis showing third-party testing. And understand that compounded drugs are not FDA-approved, which means your insurance won't cover them and you have less regulatory protection if something goes wrong. The cost savings are real, but so are the risks.

Open enrollment is your window

If you're considering GLP-1 treatment, open enrollment (typically November 1 through January 15 for marketplace plans, and your employer's window, which often falls in October or November) is the time to make plan changes.

Start with the formulary document. Pick up the one for each plan you're considering and search for semaglutide or tirzepatide by name. Check which tier it falls on. Tier 1 or 2 means lower copays. Tier 3 or higher means significantly more out of pocket, or possibly a requirement to use a specialty pharmacy.

Compare total annual cost, not just the monthly premium. A plan with a higher premium but better drug coverage could save you thousands if you're filling a $1,000-plus prescription every month. Run the actual numbers: twelve months of copays plus twelve months of premiums plus your deductible.

If you're eligible for an HSA-compatible high-deductible plan, that combination (HDHP plus HSA plus GLP-1 coverage) is often the most tax-efficient setup. You pay the deductible out of pre-tax HSA funds, then your plan's drug coverage kicks in.

What this costs you over a year

Let me put some rough numbers on the table. Say you're a commercially insured patient whose plan covers Wegovy at a Tier 3 copay of $150 per month after meeting a $2,000 deductible.

Your first-year cost: $2,000 deductible plus roughly $1,500 in copays (ten months after the deductible), totaling around $3,500 out of pocket. If you're paying from an HSA in the 22% bracket, the tax savings bring the effective cost closer to $2,700.

Compare that to the self-pay LillyDirect path for Zepbound at $399 per month: about $4,788 per year, with no tax advantage unless you're using HSA funds.

Or the Medicare Bridge Program: $600 per year. Period.

The spread between the best and worst scenarios is enormous, which is exactly why it's worth spending an hour on the phone with your insurer before your next refill.

The bottom line

GLP-1 medications are expensive, but the actual price you pay depends almost entirely on how you structure the payment. Call your insurer, check manufacturer programs, use pre-tax accounts, and, if you're on Medicare, look into the bridge program before assuming you can't afford treatment. Open enrollment this fall is your best chance to set up the right plan for 2027. An hour of research now could save you thousands over the next year.